Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · 2019 · 42 citations · 15 references
PharmacyCommunity PharmacyPharmacy PracticePharmaceutical CarePharmacy CommunicationPublic Health PharmacyCommunity Pharmacy AdministrationMedication DeprescribingMedication ReviewPharmacy LeadershipPlan-do-study-act CyclesQuality Improvement In ImplementationDeprescribing BarriersDeprescribing FacilitatorsExploratory Case StudyMedication Process ImprovementPdsa Cycle DesignPdsa Cycle ImplementationPdsa Cycle MeasurementQualitative Data Collection
BACKGROUND: There is growing international emphasis on deprescribing, involving the monitored reduction or stopping of medications that are no longer needed or that cause more harm than benefits, especially for the elderly. Community pharmacists are well positioned to partner with patients and their other health care providers in facilitating deprescribing activities. OBJECTIVE: To build community pharmacists' capacity to integrate deprescribing into their daily practices through training and workflow strategies. METHODS: This study used an exploratory mixed-methods (primarily qualitative) design. Staff at 4 Ontario pharmacies were trained to use deprescribing guidelines. Qualitative data were collected through field observations, notes from advisory group meetings and documented Plan-Do-Study-Act (PDSA) plans. Quantitative data were derived from process and output measures reported by the pharmacies. Iterative PDSA cycles allowed the project team to appraise and accelerate process improvements over time and to summarize findings on facilitators, barriers and the adaptation of processes. RESULTS: All 4 pharmacies identified individual and common goals related to deprescribing; however, drugs targeted and use of professional services to identify and address deprescribing opportunities varied. Each demonstrated that deprescribing activities could be integrated into daily practice and workflow. Common themes characterized approaches taken by each pharmacy: (1) processes used for capacity building among staff to identify patients for possible deprescribing, (2) approaches for preliminary interactions with patients, (3) in-depth medication reviews and (4) follow-up and monitoring. Approaches changed over time. CONCLUSION: 2019;152:xx-xx.
15
Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline.
Barbara Farrell, Kevin Pottie, Wade Thompson et al. · PubMed · 2017 · 386 citations
Polypharmacy Status as an Indicator of Mortality in an Elderly Population
Johanna Jyrkkä, Hannes Enlund, Maarit Jaana Korhonen et al. · Drugs & Aging · 2009 · 357 citations
Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline.
Kevin Pottie, Wade Thompson, Simon Davies et al. · PubMed · 2018 · 251 citations